Low serum adiponectin levels in subjects born small for gestational age: impact on insulin sensitivity

D Jaquet1, S Deghmoun, D Chevenne

  • 1INSERM Unit 690, Hôpital R. Debré, Paris, France.

Insights

Individuals born small for gestational age (SGA) exhibit lower adiponectin levels in adulthood, impacting insulin sensitivity. This study explores the link between reduced fetal growth, adiponectin, and metabolic health.

Area of Science:

  • Endocrinology
  • Metabolic Health
  • Perinatal Medicine

Background:

  • Adipose tissue plays a crucial role in insulin resistance, particularly in individuals with reduced fetal growth.
  • Adiponectin, an adipokine produced by adipose tissue, possesses insulin-sensitizing properties.
  • The long-term metabolic consequences of being born small for gestational age (SGA) require further investigation.

Purpose of the Study:

  • To investigate the impact of being born small for gestational age (SGA) on adult adiponectin production.
  • To examine the relationship between adiponectin levels and insulin sensitivity in SGA individuals compared to appropriate for gestational age (AGA) controls.

Main Methods:

  • Serum adiponectin concentrations were measured in 486 young adults born SGA and 573 age-matched AGA controls.
  • Insulin-resistance indices were assessed using oral glucose tolerance tests (OGTT).
  • Statistical analyses compared adiponectin levels and their correlation with insulin resistance between the SGA and AGA groups.

Main Results:

  • Adults born SGA showed significantly lower serum adiponectin levels compared to AGA controls (P = 0.02).
  • The reduced adiponectin levels in the SGA group persisted after accounting for regulatory factors (P = 0.008).
  • In AGA individuals, adiponectin negatively correlated with insulin resistance; however, this relationship was U-shaped in the SGA group.

Conclusions:

  • Reduced serum adiponectin levels in adulthood are associated with being born small for gestational age (SGA).
  • The relationship between adiponectin and insulin resistance differs between SGA and AGA individuals.
  • These findings highlight the adipose tissue's contribution to metabolic complications linked to reduced fetal growth.
Abstract

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...